14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Predictive classification models and targets identification for betulin derivatives as Leishmania donovani inhibitors

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Betulin derivatives have been proven effective in vitro against Leishmania donovani amastigotes, which cause visceral leishmaniasis. Identifying the molecular targets and molecular mechanisms underlying their action is a currently an unmet challenge. In the present study, we tackle this problem using computational methods to establish properties essential for activity as well as to screen betulin derivatives against potential targets. Recursive partitioning classification methods were explored to develop predictive models for 58 diverse betulin derivatives inhibitors of L. donovani amastigotes. The established models were validated on a testing set, showing excellent performance. Molecular fingerprints FCFP_6 and ALogP were extracted as the physicochemical properties most extensively involved in separating inhibitors from non-inhibitors. The potential targets of betulin derivatives inhibitors were predicted by in silico target fishing using structure-based pharmacophore searching and compound-pharmacophore-target-pathway network analysis, first on PDB and then among L. donovani homologs using a PSI-BLAST search. The essential identified proteins are all related to protein kinase family. Previous research already suggested members of the cyclin-dependent kinase family and MAP kinases as Leishmania potential drug targets. The PSI-BLAST search suggests two L. donovani proteins to be especially attractive as putative betulin target, heat shock protein 83 and membrane transporter D1.

          Electronic supplementary material

          The online version of this article (10.1186/s13321-018-0291-x) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references50

          • Record: found
          • Abstract: found
          • Article: not found

          Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

          Visceral leishmaniasis (VL) is a systemic protozoan disease that is transmitted by phlebotomine sandflies. Poor and neglected populations in East Africa and the Indian sub-continent are particularly affected. Early and accurate diagnosis and treatment remain key components of VL control. In addition to improved diagnostic tests, accurate and simple tests are needed to identify treatment failures. Miltefosine, paromomycin and liposomal amphotericin B are gradually replacing pentavalent antimonials and conventional amphotericin B as the preferred treatments in some regions, but in other areas these drugs are still being evaluated in both mono- and combination therapies. New diagnostic tools and new treatment strategies will only have an impact if they are made widely available to patients.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            SLC transporters as therapeutic targets: emerging opportunities.

            Solute carrier (SLC) transporters - a family of more than 300 membrane-bound proteins that facilitate the transport of a wide array of substrates across biological membranes - have important roles in physiological processes ranging from the cellular uptake of nutrients to the absorption of drugs and other xenobiotics. Several classes of marketed drugs target well-known SLC transporters, such as neurotransmitter transporters, and human genetic studies have provided powerful insight into the roles of more-recently characterized SLC transporters in both rare and common diseases, indicating a wealth of new therapeutic opportunities. This Review summarizes knowledge on the roles of SLC transporters in human disease, describes strategies to target such transporters, and highlights current and investigational drugs that modulate SLC transporters, as well as promising drug targets.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Iterated profile searches with PSI-BLAST--a tool for discovery in protein databases.

                Bookmark

                Author and article information

                Contributors
                leo.ghemtio@helsinki.fi
                Journal
                J Cheminform
                J Cheminform
                Journal of Cheminformatics
                Springer International Publishing (Cham )
                1758-2946
                17 August 2018
                17 August 2018
                2018
                : 10
                : 40
                Affiliations
                [1 ]ISNI 0000 0004 0410 2071, GRID grid.7737.4, Centre for Drug Research, Division of Pharmaceutical Biosciences, , University of Helsinki, ; Viikinkaari 5E, P.O. Box 56, 00790 Helsinki, Finland
                [2 ]ISNI 0000 0004 0410 2071, GRID grid.7737.4, Faculty of Pharmacy, Division of Pharmaceutical Chemistry and Technology, , University of Helsinki, ; Viikinkaari 5E, P.O. Box 56, 00790 Helsinki, Finland
                Author information
                http://orcid.org/0000-0003-3591-5676
                Article
                291
                10.1186/s13321-018-0291-x
                6097978
                30120601
                c7d7872d-c179-4872-920d-df34f15af2d1
                © The Author(s) 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 1 December 2017
                : 21 July 2018
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2018

                Chemoinformatics
                leishmania donovani inhibitors,betulin derivatives,predictive modeling,classification models,recursive partitioning,in silico target prediction,structure-based pharmacophore,network analysis

                Comments

                Comment on this article